Is Vaccinex Stock a Good Investment?
Vaccinex Investment Advice | VCNX |
- Examine Vaccinex's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vaccinex's leadership team and their track record. Good management can help Vaccinex navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vaccinex's business and its evolving consumer preferences.
- Compare Vaccinex's performance and market position to its competitors. Analyze how Vaccinex is positioned in terms of product offerings, innovation, and market share.
- Check if Vaccinex pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vaccinex's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vaccinex stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vaccinex is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Vaccinex Stock
Researching Vaccinex's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 49.0% of the company outstanding shares are owned by institutional investors. The company recorded earning per share (EPS) of 7.42. Vaccinex had not issued any dividends in recent years. The entity had 1:14 split on the 20th of February 2024.
To determine if Vaccinex is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vaccinex's research are outlined below:
| Vaccinex generated a negative expected return over the last 90 days | |
| Vaccinex has high historical volatility and very poor performance | |
| Vaccinex has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 570 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (13.7 M). | |
| Vaccinex currently holds about 11.4 M in cash with (17.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Vaccinex has a poor financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Vaccinex reports Q3 figures |
Vaccinex uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vaccinex. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vaccinex's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Vaccinex's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaccinex is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaccinex backward and forwards among themselves. Vaccinex's institutional investor refers to the entity that pools money to purchase Vaccinex's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 0.0 | Tacita Capital Inc. | 2024-06-30 | 0.0 | Point72 Asset Management, L.p. | 2024-06-30 | 116.5 K | Armistice Capital, Llc | 2024-06-30 | 94 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.2 K | Tower Research Capital Llc | 2024-06-30 | 1.3 K | Group One Trading, Lp | 2024-06-30 | 67.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 53.0 | Royal Bank Of Canada | 2024-06-30 | 39.0 | Bank Of America Corp | 2024-06-30 | 8.0 | Capital Advisors, Ltd. Llc | 2024-09-30 | 3.0 |
Vaccinex's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.64 M.Market Cap |
|
Vaccinex's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.58) | (5.86) | |
| Return On Capital Employed | 10.02 | 10.52 | |
| Return On Assets | (5.58) | (5.86) | |
| Return On Equity | 8.76 | 9.20 |
Determining Vaccinex's profitability involves analyzing its financial statements and using various financial metrics to determine if Vaccinex is a good buy. For example, gross profit margin measures Vaccinex's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vaccinex's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Vaccinex's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaccinex. Check Vaccinex's Beneish M Score to see the likelihood of Vaccinex's management manipulating its earnings.
Evaluate Vaccinex's management efficiency
Vaccinex has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Vaccinex's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 9.20 in 2024, whereas Return On Tangible Assets are likely to drop (5.86) in 2024. At this time, Vaccinex's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 8.9 M in 2024, whereas Non Currrent Assets Other are likely to drop (1.05) in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (4.98) | (4.74) | |
| Tangible Book Value Per Share | (4.98) | (4.74) | |
| Enterprise Value Over EBITDA | (0.15) | (0.16) | |
| Price Book Value Ratio | (1.87) | (1.96) | |
| Enterprise Value Multiple | (0.15) | (0.16) | |
| Price Fair Value | (1.87) | (1.96) | |
| Enterprise Value | 3 M | 2.9 M |
Leadership effectiveness at Vaccinex is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.985 |
Basic technical analysis of Vaccinex Stock
As of the 21st of November, Vaccinex has the Variance of 74.9, coefficient of variation of (7,105), and insignificant Risk Adjusted Performance. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaccinex, as well as the relationship between them.Vaccinex's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaccinex insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaccinex's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaccinex insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaccinex's Outstanding Corporate Bonds
Vaccinex issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaccinex uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaccinex bonds can be classified according to their maturity, which is the date when Vaccinex has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Vaccinex's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vaccinex's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 5.97 | |||
| Coefficient Of Variation | (7,105) | |||
| Standard Deviation | 8.65 | |||
| Variance | 74.9 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (1.11) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 54.95 | |||
| Value At Risk | (14.00) | |||
| Potential Upside | 11.11 | |||
| Skewness | (1.04) | |||
| Kurtosis | 3.49 |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 5.97 | |||
| Coefficient Of Variation | (7,105) | |||
| Standard Deviation | 8.65 | |||
| Variance | 74.9 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (1.11) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 54.95 | |||
| Value At Risk | (14.00) | |||
| Potential Upside | 11.11 | |||
| Skewness | (1.04) | |||
| Kurtosis | 3.49 |
Consider Vaccinex's intraday indicators
Vaccinex intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vaccinex stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Vaccinex Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 25th of October 2024 Other Reports | ViewVerify | |
| 16th of October 2024 Other Reports | ViewVerify |
Vaccinex Stock media impact
Far too much social signal, news, headlines, and media speculation about Vaccinex that are available to investors today. That information is available publicly through Vaccinex media outlets and privately through word of mouth or via Vaccinex internal channels. However, regardless of the origin, that massive amount of Vaccinex data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vaccinex news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vaccinex relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vaccinex's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vaccinex alpha.
Vaccinex Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vaccinex can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vaccinex Corporate Management
| Jill CPA | Chief Officer | Profile | |
| Jill Sanchez | Interim Controller | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ernest Smith | Senior Officer | Profile | |
| Maurice Zauderer | CEO, CoFounder | Profile | |
| Elizabeth Evans | COO Medicine | Profile | |
| John Leonard | Senior Development | Profile |
Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.